Stephen H. Zinner

Stephen H. Zinner's AcademicInfluence.com Rankings

Stephen H. Zinner

Philosophy

#8599

World Rank

#12009

Historical Rank

Logic

#5632

World Rank

#7044

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Stephen H. Zinner's Degrees

Masters Medicine Harvard University
Bachelors Chemistry Harvard University

Why Is Stephen H. Zinner Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Stephen H. Zinner's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance (1987) (485)
Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. (1978) (463)
Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. (1999) (410)
Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. (1987) (347)
Familial aggregation of blood pressure in childhood. (1971) (306)
Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer (1995) (239)
Efficacy and Toxicity of Single Daily Doses of Amikacin and Ceftriaxone versus Multiple Daily Doses of Amikacin and Ceftazidime for Infection in Patients with Cancer and Granulocytopenia (1993) (235)
In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus (2003) (223)
Fifteen-month follow-up study of women infected with Chlamydia trachomatis. (1979) (180)
Risk of local and systemic infection with polyethylene intravenous catheters. A prospective study of 213 catheterizations. (1968) (174)
2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. (1993) (172)
Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients (1986) (167)
Stability of Blood Pressure Rank and Urinary Kallikrein Concentration in Childhood: An Eight-Year Follow-Up (1978) (160)
Sexual behavior of college women in 1975, 1986, and 1989. (1990) (157)
Synergistic combinations of antibiotics in gram-negative bacillary infections. (1982) (150)
Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. (2003) (148)
A longitudinal study of blood pressure in childhood. (1974) (147)
Familial aggregation of urinary kallikrein concentration in childhood: relation to blood pressure, race and urinary electrolytes. (1976) (143)
Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). (2008) (127)
Risk of infection with intravenous indwelling catheters: effect of application of antibiotic ointment. (1969) (125)
Vaginal colonization with group B streptococcus: a study in college women. (1977) (121)
Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. (2003) (120)
Two compartment kinetic model with multiple artificial capillary units. (1985) (120)
Effects of IgM and IgG antibody in patients with bacteremia due to gram-negative bacilli. (1976) (112)
Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. (1988) (110)
Vaginal colonization with Corynebacterium vaginale (Haemophilus vaginalis). (1977) (109)
Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperati (1991) (104)
Sexual experience and urethral colonization with genital mycoplasmas. A study in normal men. (1973) (104)
Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model (1985) (98)
Significance of blood pressure in infancy. Familial aggregation and predictive effect on later blood pressure. (1985) (92)
Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. (2006) (92)
Infection with Chlamydia trachomatis in female college students. (1985) (90)
Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model. (1999) (90)
Antistaphylococcal activity of rifampin with other antibiotics. (1981) (88)
Expanding indications for the new macrolides, azalides, and streptogramins. (1997) (80)
The Prevalence of Dyspareunia (1990) (73)
Gram-positive bacteraemia in granulocytopenic cancer patients. (1990) (66)
Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. (1994) (65)
Maternal Prenatal Dietary Potassium, Calcium, Magnesium, and Infant Blood Pressure (1991) (64)
Inter- and Intraquinolone Predictors of Antimicrobial Effect in an In Vitro Dynamic Model: New Insight into a Widely Used Concept (1998) (64)
Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection (1993) (62)
Long-term (10 to 14 years) follow-up of bacteriuria of pregnancy. (1971) (61)
Burden of antimicrobial resistance in an era of decreasing susceptibility (2017) (57)
Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection (1994) (49)
Chlamydia trachomatis in women: antibody in cervical secretions as a possible indicator of genital infection. (1979) (47)
ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. (2004) (47)
Vaginal Colonization with Mycoplasma hominis and Ureaplasma urealyticum (1986) (45)
Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection. (1991) (44)
Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. (2004) (41)
Microencapsulation of erythromycin and clarithromycin using a spray-drying technique. (1999) (40)
A New Approach to In Vitro Comparisons of Antibiotics in Dynamic Models: Equivalent Area under the Curve/MIC Breakpoints and Equiefficient Doses of Trovafloxacin and Ciprofloxacin against Bacteria of Similar Susceptibilities (1998) (39)
Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion. (2008) (37)
Bacteriuria and renal disease. (1969) (37)
Fosfomycin trometamol versus pipemidic acid in the treatment of bacteriuria in pregnancy. (1990) (36)
Bacterial pathogens of increasing significance in hospital-acquired infections. (1985) (35)
Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model (1985) (35)
The effects of sodium, chloride, and calcium concentration on the response of melanophores to melanocyte-stimulating hormone (MSH). (1962) (35)
Isolation of Eikenella corrodens in a General Hospital (1973) (35)
Bacterial Resistance Studies Using In Vitro Dynamic Models: the Predictive Power of the Mutant Prevention and Minimum Inhibitory Antibiotic Concentrations (2013) (34)
Antibiotic use: present and future. (2007) (34)
Profile of a Novel Anionic Fluoroquinolone—Delafloxacin (2019) (34)
In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus (1981) (33)
Neonatal Blood Pressure and Salt Taste Responsiveness (2002) (32)
Significance of "extravascular" protein binding for antimicrobial pharmacodynamics in an in vitro capillary model of infection (1990) (32)
Prediction of the Effects of Inoculum Size on the Antimicrobial Action of Trovafloxacin and Ciprofloxacin againstStaphylococcus aureus and Escherichia coli in an In Vitro Dynamic Model (1999) (32)
Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models (1987) (31)
Symptoms associated with vaginal colonization with yeast. (1988) (31)
Pathogenesis of Urinary Tract Infection (1988) (31)
Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. (2000) (31)
Enrichment of Fluoroquinolone-Resistant Staphylococcus aureus: Oscillating Ciprofloxacin Concentrations Simulated at the Upper and Lower Portions of the Mutant Selection Window (2008) (30)
Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin (1986) (30)
The search for new antimicrobials: why we need new options (2005) (30)
Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline. (2008) (29)
An artificial capillary in vitro kinetic model of antibiotic bactericidal activity. (1981) (29)
Sexually transmitted conditions among women college students. (1981) (28)
In vitro models for the study of antibiotic activities. (1987) (27)
AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. (2002) (26)
Concentration-dependent changes in the susceptibility and killing of Staphylococcus aureus in an in vitro dynamic model that simulates normal and impaired gatifloxacin elimination. (2004) (25)
Relationships of the Area under the Curve/MIC Ratio to Different Integral Endpoints of the Antimicrobial Effect: Gemifloxacin Pharmacodynamics in an In Vitro Dynamic Model (2001) (24)
Limited protective effect of rough mutant antisera in murine Escherichia coli bacteremia (1982) (24)
Bacteriuria and babies revisited. (1979) (24)
Single daily dosing of amikacin in an in-vitro model. (1991) (23)
Overview of antibiotic use and resistance: setting the stage for tigecycline. (2005) (23)
Antistaphylococcal Effect Related to the Area under the Curve/MIC Ratio in an In Vitro Dynamic Model: Predicted Breakpoints versus Clinically Achievable Values for Seven Fluoroquinolones (2005) (23)
Comparative Pharmacodynamics of Gatifloxacin and Ciprofloxacin in an In Vitro Dynamic Model: Prediction of Equiefficient Doses and the Breakpoints of the Area under the Curve/MIC Ratio (2000) (23)
In Vitro Resistance Studies with Bacteria That Exhibit Low Mutation Frequencies: Prediction of “Antimutant” Linezolid Concentrations Using a Mixed Inoculum Containing both Susceptible and Resistant Staphylococcus aureus (2014) (22)
MIC-Based Interspecies Prediction of the Antimicrobial Effects of Ciprofloxacin on Bacteria of Different Susceptibilities in an In Vitro Dynamic Model (1998) (22)
The Incidence of Genitourinary Infections in a Cohort of Healthy Women (1994) (21)
Puerperal bacteremia and neonatal sepsis due to Hemophilus parainfluenzae: report of a case with antibody titers. (1972) (21)
New pathogens in neutropenic patients with cancer: an update for the new millennium. (2000) (21)
Synergistic Activity of Trimethoprim and Amikacin Against Gram-Negative Bacilli (1977) (21)
Effect of dose and schedule on cefoperazone pharmacodynamics in an in vitro model of infection in a neutropenic host. (1988) (21)
The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models. (2009) (20)
Predicting bacterial resistance using the time inside the mutant selection window: possibilities and limitations. (2014) (19)
Predictors of Effect of Ampicillin-Sulbactam against TEM-1 β-Lactamase-Producing Escherichia coli in an In Vitro Dynamic Model: Enzyme Activity versus MIC (2006) (19)
Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration. (2016) (18)
Comparison of methods for the isolation of genital mycoplasmas from men. (1976) (18)
Use of an in-vitro kinetic model to study antibiotic combinations. (1985) (18)
Pharmacokinetically-based prediction of the effects of antibiotic combinations on resistant Staphylococcus aureus mutants: in vitro model studies with linezolid and rifampicin (2017) (17)
Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model. (2004) (17)
Factors affecting blood pressures in newborn infants (1980) (17)
Clinical Overview of Enoxacin (1989) (17)
Effect of mixing on rifampin bactericidal activity against staphylococci (1981) (17)
Time inside the mutant selection window as a predictor of staphylococcal resistance to linezolid (2018) (16)
Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model. (2013) (16)
Comparative pharmacodynamics of azithromycin and roxithromycin with S. pyogenes and S. pneumoniae in a model that simulates in vitro pharmacokinetics in human tonsils. (2002) (16)
Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models (2015) (15)
Use of modeling techniques to aid in antibiotic selection (2001) (15)
Erythromycin and alkalinisation of urine in the treatment of urinary-tract infections due to gram-negative bacilli. (1971) (14)
Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses. (2000) (14)
How Early Can the Tendency toward Hypertension Be Detected (1969) (14)
Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. (2008) (13)
Early granulocyte transfusions in high risk febrile neutropenic patients. (1983) (13)
Factors affecting blood pressures in newborn infants. (1980) (13)
The Antistaphylococcal Pharmacodynamics of Linezolid Alone and in Combination with Doxycycline in an In Vitro Dynamic Model (2011) (13)
The emerging problem of bacterial resistance in cancer patients; proceedings of a workshop held by MASCC “Neutropenia, Infection and Myelosuppression” Study Group during the MASCC annual meeting held in Berlin on 27–29 June 2013 (2016) (12)
Activity of Trovafloxacin (with or without Ampicillin-Sulbactam) against Enterococci in an In Vitro Dynamic Model of Infection (1998) (12)
Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Studies in vivo and in an in vitro dynamic model. (1987) (12)
In Vitro Dynamic Models as Tools to Predict Antibiotic Pharmacodynamics (2007) (12)
New Considerations for Macrolides, Azalides, Streptogramins, and Ketolides (1999) (11)
Erythromycin plus alkalinization in treatment of urinary infections. (1969) (11)
Predicting antibiotic combination effects on the selection of resistant Staphylococcus aureus: In vitro model studies with linezolid and gentamicin. (2018) (11)
Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model (2017) (11)
Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. (2009) (11)
Enhancement of leucocyte killing of resistant bacteria selected during exposure to aminoglycosides or quinolones. (1990) (11)
Serum Bactericidal Activity of Moxalactam and Cefotaxime With and Without Tobramycin Against Pseudomonas aeruginosa and Staphylococcus aureus (1981) (11)
In vitro models for the study of combination antibiotic therapy in neutropenic patients. (1986) (11)
Bactericidal activity of ciprofloxacin alone and in combination with azlocillin in an in-vitro capillary model. (1986) (11)
The potential role of cell wall core glycolipids in the immunoprophylaxis and immunotherapy of gram-negative rod bacteraemia (1983) (10)
Comparison of tube dilution and microtitre methods for the detection of antibiotic tolerance in strains of Staphylococcus aureus. (1984) (10)
In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods. (1986) (10)
Rapid method for determining serum bactericidal activity. (1974) (10)
Effect of Clindamycin on the In Vitro Activity of Amikacin and Gentamicin Against Gram-Negative Bacilli (1976) (10)
Sulfonamides and Trimethoprim (2015) (10)
Bacterial antibiotic resistance studies using in vitro dynamic models: Population analysis vs. susceptibility testing as endpoints of mutant enrichment. (2015) (10)
Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. (2005) (10)
Simulated in vitro Quinolone Pharmacodynamics at Clinically Achievable AUC/MIC Ratios: Advantage of IE over Other Integral Parameters (2003) (9)
Macrolides: a clinical overview (2002) (9)
BLOOD PRESSURE IN INFANCY (1956) (9)
Comparative Activities of Ciprofloxacin and Levofloxacin againstStreptococcus pneumoniae in an In Vitro Dynamic Model (2000) (8)
Opsonization of serum-sensitive and serum-resistant Escherichia coli by rough mutant (Re) antisera. (1982) (8)
Panic attacks precipitated by sertraline. (1994) (8)
Comparative Pharmacodynamics and Antimutant Potentials of Doripenem and Imipenem with Ciprofloxacin-Resistant Pseudomonas aeruginosa in an In Vitro Model (2011) (8)
Fluoroquinolone prophylaxis in patients with neutropenia. (2005) (8)
Bacteriology of the human gallbladder in cholelithiasis and cholecystitis. (1983) (8)
Relevant aspects in the Infectious Diseases Society of America (IDSA) guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. (1998) (8)
Antimicrobial therapy in cancer patients: Studies from the EORTC international antimicrobial therapy cooperative group (1997) (7)
Management of urinary tract infections in pregnancy: A review with comments on single dise therapy (1992) (7)
Countercurrent immunoelectrophoresis in the diagnosis of viral infections of the central nervous system. (1978) (7)
In vitro models in the study of antibiotic therapy of infections in neutropenic patients. (1986) (7)
Studies on the origin of human hypertension. (1977) (7)
Net Effect of Inoculum Size on Antimicrobial Action of Ampicillin-Sulbactam: Studies Using an In Vitro Dynamic Model (2006) (6)
Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections (1990) (6)
Combinations of antibiotics for therapy of severe infections in cancer patients (1980) (6)
Prospective Randomized Comparison of Three Antibiotic Regimens for Empirical Therapy of Suspected Bacteremic Infection in Febrile Granulocytopenic Patients (1986) (6)
In vitro dynamic model for determining the comparative pharmacology of fluoroquinolones. (1999) (6)
New and unusual infections in neutropenic patients. (1995) (6)
Review of amikacin usage in the EORTC trials. (1985) (5)
Predicting effects of antibiotic combinations using MICs determined at pharmacokinetically derived concentration ratios: in vitro model studies with linezolid- and rifampicin-exposed Staphylococcus aureus (2017) (5)
Concentration-response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model. (2007) (5)
Management of urinary tract infections in pregnancy: a review with comments on single dose therapy. (1992) (5)
A novel parameter to predict the effects of antibiotic combinations on the development of Staphylococcus aureus resistance: in vitro model studies at subtherapeutic daptomycin and rifampicin exposures (2019) (5)
Brief Review of Fungal Infections (1990) (5)
Sexual behavior and contraceptive use. Changes from 1975 to 1995 in college women. (1997) (5)
A comparative study of methods for the detection of antibodies to core glycolipids. (1979) (5)
Concentration-dependent enrichment of resistant Enterococcus faecium exposed to linezolid in an in vitro dynamic model (2018) (5)
Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC (1996) (5)
Comparative pharmacodynamics of telithromycin and clarithromycin with Streptococcus pneumoniae and Staphylococcus aureus in an in vitro dynamic model: focus on clinically achievable antibiotic concentrations. (2005) (4)
The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses. (2001) (4)
Efficacy of standard disc-diffusion test as applied to susceptibility of Staphylococcus aureus to tetracycline and minocycline. (1972) (4)
In-vitro activity of aztreonam in combination with four other antibiotics against gram-negative bacilli and Staphylococcus aureus. (1984) (4)
Verification of a Novel Approach to Predicting Effects of Antibiotic Combinations: In Vitro Dynamic Model Study with Daptomycin and Gentamicin against Staphylococcus aureus (2020) (4)
Cefotaxime and amikacin: results of in vitro and in vivo studies against Gram-negative bacteria and Staphylococcus aureus. EORTC International Antimicrobial Therapy Project Group. (1980) (4)
Maximizing antimicrobial efficacy, minimizing antimicrobial resistance: a paradigm for the new millennium. Proceedings of a symposium. Cambridge, Massachusetts, USA. 7-8 December 1999. (2001) (4)
Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model. (2002) (4)
Resistance studies with Streptococcus pneumoniae using an in vitro dynamic model: amoxicillin versus azithromycin at clinical exposures (2019) (4)
Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model. (2002) (3)
Species differences in ciprofloxacin resistance among Gram-negative bacteria: can “anti-mutant” ratios of the area under the concentration–time curve to the MIC be achieved clinically? (2017) (3)
Predicting the antistaphylococcal effects of daptomycin–rifampicin combinations in an in vitro dynamic model (2019) (3)
In-vitro interaction of azithromycin and fluoroquinolones against gram-positive and gram-negative bacteria. (1996) (3)
Gram-negative rod bacteremia in cancer patients. A review with emphasis on the antibody response. (1975) (3)
Approach to fever in the neutropenic host. (1998) (3)
Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships. (2001) (3)
In vitro antimicrobial activity of moxifloxacin against bacterial strains isolated from blood of neutropenic cancer patients (2006) (3)
Evaluation of self-obtained cultures using a vaginal tampon as a method of screening for asymptomatic gonorrhea on a college campus. (1974) (3)
In vitro Models as Predictors of the Antimicrobial Effect of Moxifloxacin and Other Fluoroquinolones (2000) (2)
Inability of counterimmunoelectrophoresis to detect echovirus in cerebrospinal fluid. (1983) (2)
Serum Inhibitory and Bactericidal Activity of Ciprofloxacin following Intravenous Administration (1989) (2)
Prophylaxis of bacterial infections with oral antibiotics in neutropenic patients. Lessons from the last two EORTC trials and prospects for the future. (1983) (2)
Cost Effectiveness of a Preventive Program in Renal Disease (1969) (2)
Type Specific and Cross Reactive Antigens of Gram-Negative Bacilli in Protection against Infection (1975) (2)
Laboratory support for choosing and monitoring antimicrobial therapy in severely ill patients. (1986) (2)
PK/PD-Based Prediction of “Anti-Mutant” Antibiotic Exposures Using In Vitro Dynamic Models (2018) (2)
P2062 Bacterial strain-independent anti-staphylococcal effects of telavancin in an in vitro dynamic model that simulates multiple-dose pharmacokinetics in humans (2007) (2)
Synergism of trimethoprim combined with aminoglycosides in vitro and in serum of volunteers (1982) (2)
Predicting the Effects of Carbapenem/Carbapenemase Inhibitor Combinations against KPC-Producing Klebsiella pneumoniae in Time-Kill Experiments: Alternative versus Traditional Approaches to MIC Determination (2021) (2)
New pathogens in the immunocompromised host. (1993) (2)
Anti-mutant efficacy of antibiotic combinations: in vitro model studies with linezolid and daptomycin. (2021) (2)
Net effect of inoculum size on antimicrobial action of ampicillin-sulbactam: studies using an in vitro dynamic model (1997) (1)
Treatment of gram-negative bacteremia in patients with cancer and granulocytopenia. (1988) (1)
The epidemiology of bacteriuria in pregnancy (1990) (1)
SESSION IV: PRESENT AND FUTURE ROLES OF QUINOLONES PROPHYLACTIC USES OF FLUOROQUINOLONE ANTIBIOTICS (1994) (1)
366 FAMILIAL AGGREGATION OF BLOOD PRESSURE IN NEWBORN INFANTS (1978) (1)
Three decades of research on sexual behavior and sexually transmitted pathogens in college students. (1997) (1)
Rapid Method for Determining Serum Bactericidal Activity (1974) (1)
College women and condom use, 1975-1995. (1996) (1)
MPC-Based Prediction of Anti-Mutant Effectiveness of Antibiotic Combinations: In Vitro Model Study with Daptomycin and Gentamicin against Staphylococcus aureus (2021) (1)
Antibiotic pharmacodynamics and bacterial resistance: Usefulness of in vitro models (2007) (1)
Antibiotic Development and the Evolving Role of Pharmacodynamics — As Good as It Gets? (2015) (0)
An antibiotic update: I. New penicillins and cephalosporins. (1975) (0)
O422 Concentration-dependent selection of resistant mutants of Enterococcus faecium exposed to linezolid in an in vitro dynamic model (2007) (0)
Pharmacokinetics andBioavailability ofIntravenous-to-Oral Enoxacin inElderly Patients withComplicated Urinary Tract Infections (1990) (0)
O425 Comparative pharmacodynamics of telavancin and vancomycin with Staphylococcus aureus: multiple-dose simulations using an in vitro dynamic model (2007) (0)
Infectious diseases 25 years into the future. (1994) (0)
Isolation of Eikenella corrodens in a General Hospital (1973) (0)
Microencapsulation of erythrom ycin and clarithrom ycin using a spray-drying technique (1999) (0)
Time inside the mutant selection window as a predictor of staphylococcal resistance to linezolid (2018) (0)
Relative Strengths of Area Under the Curve (AUC)/MIC or AUC/MPC as Predictors of Staphylococcus aureus Resistance During Exposure to Fluctuating and Constant Fluoroquinolone Concentrations Within the Mutant Selection Window (2008) (0)
Subject Index Vol. 48, 2002 (2003) (0)
Evaluation of the pharmacodynamics of Daptomycin (DAP)-Rifampin (RIF) combinations with Staphylococcus aureus using various in vitro methods (2010) (0)
College women and condom use 1975-1995 [letter] (1996) (0)
Preface (2008) (0)
Microencapsulation of HIV antigen: Potential application of the spray-drying technique. (1993) (0)
International conference on in vitro models of antibiotic dosing (1985) (0)
Contents Vol. 48, 2002 (2003) (0)
Paul Ehrlich, a prescient pioneer in the field of antimicrobial chemotherapy: what did he foresee a century ago? (2013) (0)
An antibiotic update: II. New aminoglycosides and other antibiotics. (1975) (0)
A Spot Plate Method for Antibiotic-Bacterial Killing Rates (1976) (0)
Klebsiella pneumoniae Susceptibility to Carbapenem/Relebactam Combinations: Influence of Inoculum Density and Carbapenem-to-Inhibitor Concentration Ratio (2022) (0)
Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des recherches pharmaceutiques (1987) (0)
Eikenella Corrodens and Other Similar Bacteria: A Review of Laboratory Aspects and Clinical Significance (1974) (0)
Testing the Mutant Selection Window (MSW) Hypothesis using In Vitro Dynamic Models: Focus on Daptomycin (2006) (0)
Book ReviewOpportunistic Infections in Patients with the Acquired Immunodeficiency Syndrome (1990) (0)
Preventing Enrichment of Daptomycin (DAP)-Resistant Staphylococcus aureus with DAP in Combination with Rifampicin (RIF) or Gentamicin (GEN) (2008) (0)
Novobiocin and acidification for treatment of bacteriuria due to gram-negative bacilli. (1969) (0)
Unusual infections in the immunocompromised host (1994) (0)
P95 PHARMACODYNAMIC PARAMETERS WHICH PREDICT INITIAL KILLING OF S. PNEUMONIAE BY FLUOROQUINOLONES AND SUBSEQUENT REGROWTH IN PHARMACOKINETIC MODELS OF INFECTION (2001) (0)
[ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy): the viewpoint of an American leader in Infectiology. Interview by E. Bergogne-Bérézin]. (1999) (0)
Predicting the antistaphylococcal effects of daptomycin–rifampicin combinations in an in vitro dynamic model (2019) (0)
Sociodemographlc Factors and Maternal Prenatal Intake of Potassium , Calcium , and Magnesium Factor Infant race White (2005) (0)
Endocarditis associated with indwelling venous catheters. (1977) (0)
Long-Term Significance Factors Affecting Blood Pressures in Newborn Infants (2005) (0)
Book Review The AIDS Disaster: The failure of organizations in New York and the nation By Charles Perrow and Mauro F. Guillén. 206 pp. New Haven, Conn., Yale University Press, 1990. $25 (cloth); $9.95 (paper). (1991) (0)
New and Unusual Infections in Neutropenic Patients with Cancer: Concern About Antibiotic-Resistant Bacteria (1999) (0)
Contributors (2015) (0)
Killing Kinetics of Staphylococcus aureus Exposed to Multiple-Dose Pharmacokinetics of Daptomycin (DAP) and Vancomycin (VAN): Focus on the Enrichment of Resistant Mutants. (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Stephen H. Zinner?

Stephen H. Zinner is affiliated with the following schools: